News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
756,234 Results
Type
Article (53919)
Company Profile (325)
Press Release (701990)
Section
Business (217966)
Career Advice (2875)
Deals (37667)
Drug Delivery (119)
Drug Development (86660)
Employer Resources (185)
FDA (17225)
Job Trends (16111)
News (370442)
Policy (36047)
Tag
2024 BioCapital Digital (12)
2024 BioForest Digital (5)
2024 BioForest Standard (1)
2024 BioMidwest Digital (9)
2024 BioMidwest Standard (1)
2024 Bio NC Digital (8)
2024 Bio NC Standard (2)
2024 Biotech Bay Standard (20)
2024 Biotech Beach Digital (10)
2024 Biotech Beach Standard (6)
2024 Genetown Digital (8)
2024 Genetown Standard (12)
2024 Lone Star Bio Digital (6)
2024 Pharm Country Digital (7)
2024 Pharm Country Standard (7)
2025 BioForest Digital (3)
2025 Lone Star Bio Digital (6)
2026 BioCapital Elite (1)
2026 BioCapital Standard (1)
2026 BioMidwest Elite (1)
2026 Biotech Bay Standard (1)
2026 Biotech Beach Elite (1)
2026 Genetown Elite (2)
2026 Pharm Country Standard (1)
Academia (2902)
Academic (1)
Accelerated approval (4)
Adcomms (27)
Allergies (88)
Alliances (53419)
ALS (93)
Alzheimer's disease (1457)
Antibody-drug conjugate (ADC) (132)
Approvals (17201)
Artificial intelligence (268)
Autoimmune disease (18)
Automation (14)
Bankruptcy (388)
Best Places to Work (12221)
BIOSECURE Act (19)
Biosimilars (112)
Biotechnology (213)
Bladder cancer (63)
Brain cancer (28)
Breast cancer (268)
Cancer (2132)
Cardiovascular disease (182)
Career advice (2411)
Career pathing (33)
CAR-T (152)
Cell therapy (429)
Cervical cancer (20)
Clinical research (70018)
Collaboration (824)
Compensation (472)
Complete response letters (28)
COVID-19 (2797)
CRISPR (43)
C-suite (229)
Cystic fibrosis (102)
Data (2027)
Decentralized trials (2)
Denatured (28)
Depression (48)
Diabetes (266)
Diagnostics (6703)
Digital health (18)
Diversity (9)
Diversity, equity & inclusion (45)
Drug discovery (121)
Drug pricing (116)
Drug shortages (30)
Duchenne muscular dystrophy (92)
Earnings (89238)
Editorial (39)
Employer branding (23)
Employer resources (158)
Events (119576)
Executive appointments (688)
FDA (18393)
Featured Employer (52)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (7)
Funding (725)
Gene editing (109)
Generative AI (23)
Gene therapy (313)
GLP-1 (790)
Government (4855)
Grass and pollen (5)
Guidances (49)
Healthcare (20118)
Huntington's disease (24)
IgA nephropathy (27)
Immunology and inflammation (123)
Indications (27)
Infectious disease (2940)
Inflammatory bowel disease (145)
Inflation Reduction Act (9)
Influenza (51)
Intellectual property (89)
Interviews (554)
IPO (17084)
IRA (49)
Job creations (4335)
Job search strategy (1994)
Kidney cancer (10)
Labor market (34)
Layoffs (514)
Leadership (20)
Legal (8959)
Liver cancer (76)
Lung cancer (313)
Lymphoma (136)
Machine learning (4)
Management (63)
Manufacturing (291)
MASH (68)
Medical device (13981)
Medtech (13986)
Mergers & acquisitions (21058)
Metabolic disorders (700)
Multiple sclerosis (78)
NASH (23)
Neurodegenerative disease (101)
Neuropsychiatric disorders (30)
Neuroscience (1995)
NextGen: Class of 2025 (7155)
Non-profit (4889)
Northern California (2497)
Now hiring (37)
Obesity (380)
Opinion (254)
Ovarian cancer (74)
Pain (89)
Pancreatic cancer (79)
Parkinson's disease (146)
Partnered (20)
Patents (216)
Patient recruitment (100)
Peanut (51)
People (62330)
Pharmaceutical (93)
Pharmacy benefit managers (19)
Phase I (21702)
Phase II (30679)
Phase III (23028)
Pipeline (1092)
Podcasts (92)
Policy (133)
Postmarket research (2970)
Preclinical (9275)
Press Release (71)
Prostate cancer (97)
Psychedelics (38)
Radiopharmaceuticals (256)
Rare diseases (396)
Real estate (6572)
Recruiting (72)
Regulatory (24358)
Reports (47)
Research institute (2572)
Resumes & cover letters (454)
Rett syndrome (4)
RNA editing (4)
RSV (43)
Schizophrenia (75)
Series A (128)
Series B (82)
Service/supplier (14)
Sickle cell disease (57)
Southern California (2156)
Special edition (16)
Spinal muscular atrophy (159)
Sponsored (31)
Startups (3917)
State (2)
Stomach cancer (16)
Supply chain (66)
Tariffs (14)
The Weekly (62)
United States (22029)
Vaccines (741)
Venture capitalists (38)
Webinars (13)
Weight loss (268)
Women's health (34)
Worklife (18)
Date
Today (104)
Last 7 days (689)
Last 30 days (2759)
Last 365 days (34985)
2025 (8667)
2024 (36825)
2023 (41748)
2022 (52982)
2021 (57654)
2020 (56522)
2019 (49805)
2018 (37731)
2017 (34734)
2016 (34701)
2015 (40733)
2014 (34842)
2013 (30212)
2012 (32199)
2011 (32811)
2010 (31015)
Location
Africa (946)
Alabama (50)
Alaska (7)
Arizona (238)
Arkansas (14)
Asia (43778)
Australia (7748)
California (5702)
Canada (1907)
China (502)
Colorado (254)
Connecticut (263)
Delaware (135)
Europe (95879)
Florida (840)
Georgia (200)
Idaho (61)
Illinois (545)
India (26)
Indiana (307)
Iowa (9)
Japan (147)
Kansas (103)
Kentucky (25)
Louisiana (8)
Maine (61)
Maryland (875)
Massachusetts (4343)
Michigan (215)
Minnesota (389)
Mississippi (2)
Missouri (83)
Montana (29)
Nebraska (25)
Nevada (56)
New Hampshire (66)
New Jersey (1630)
New Mexico (30)
New York (1635)
North Carolina (1004)
North Dakota (7)
Northern California (2497)
Ohio (195)
Oklahoma (14)
Oregon (39)
Pennsylvania (1283)
Puerto Rico (10)
Rhode Island (29)
South America (1327)
South Carolina (18)
South Dakota (1)
Southern California (2156)
Tennessee (98)
Texas (853)
Utah (170)
Virginia (142)
Washington D.C. (62)
Washington State (540)
West Virginia (3)
Wisconsin (51)
756,234 Results for "casi pharmaceuticals formerly known as entremed inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
CASI Pharmaceuticals Announces Fourth Quarter and Full-Year 2024 Business and Financial Results
April 1, 2025
·
14 min read
Press Releases
CASI Pharmaceuticals Announces Receipt of An Updated Non-Binding Proposal to Acquire Entire China Business of the Company
April 3, 2025
·
7 min read
Business
CASI PHARMACEUTICALS ANNOUNCES FIRST QUARTER 2024 BUSINESS AND FINANCIAL RESULTS
CASI Pharmaceuticals, Inc. today reported financial results for the three months ended March 31, 2024.
May 14, 2024
·
10 min read
Drug Development
CASI Pharmaceuticals Receives FDA Clearance On The Investigational New Drug (IND) Application For CID-103 In Immune Thrombocytopenia (ITP)
CASI Pharmaceuticals, Inc. announced today the following: On April 12, 2024 CASI submitted the IND application to the FDA for CID-103 to support a phase 1/2 study of CID-103 in adults with chronic Immune Thrombocytopenia (ITP).
May 15, 2024
·
5 min read
CASI Pharmaceuticals Reports Development Relating to Its Disputes With Juventas
CASI Pharmaceuticals, Inc. reported that it has furnished a current report on Form 6-K to disclose material development relating to its dispute with Juventas.
April 8, 2024
·
5 min read
Press Releases
Averna Therapeutics, formerly known as Exsilio Therapeutics, Appoints Thomas M. Barnes, Ph.D., as Chief Executive Officer
January 27, 2025
·
3 min read
CASI Pharmaceuticals Announces First Dosing of FOLOTYN® in China
CASI Pharmaceuticals, Inc., a biopharmaceutical company specializing in the development and commercialization of innovative therapeutic and pharmaceutical products, proudly announced the administration of the first dose of FOLOTYN® to a patient in China.
February 16, 2024
·
6 min read
Business
CASI Pharmaceuticals Announces Fourth Quarter and Full-Year 2023 Business and Financial Results
CASI Pharmaceuticals, Inc. reported business and financial results for the year ended December 31, 2023, and provided an update on key highlights for 2023.
March 28, 2024
·
17 min read
Press Releases
CASI Pharmaceuticals Announces Third Quarter 2024 Business and Financial Results
November 15, 2024
·
10 min read
CASI Pharmaceuticals Announces $15 Million Private Placement Financing by Venrock Healthcare Capital Partners, Foresite Capital, Panacea Venture and Dr. Wei-Wu He
CASI Pharmaceuticals, Inc. announced that it has entered into securities purchase agreements with certain investors for a private investment in public equity financing that is expected to result in aggregate gross proceeds of approximately $15.0 million, before deducting placement agent fees and other private placement expenses.
June 26, 2024
·
7 min read
1 of 75,624
Next
